{
    "organizations": [],
    "uuid": "b0563d9ceb868cc40730135fbc6d42ad6a0283e8",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-aurinia-reports-qtrly-loss-per-sha/brief-aurinia-reports-qtrly-loss-per-share-0-18-idUSASC0A1JM",
    "ord_in_thread": 0,
    "title": "BRIEF-Aurinia Reports Qtrly Loss Per Share $0.18",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 10 (Reuters) - Aurinia Pharmaceuticals Inc:\n* AURINIA REPORTS FIRST QUARTER FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS\n* AURINIA PHARMACEUTICALS INC - AURORA PHASE III TRIAL IN LUPUS NEPHRITIS REMAINS ON TRACK\n* AURINIA PHARMACEUTICALS INC - CONTINUE TO BE WELL-CAPITALIZED INTO 2020\n* AURINIA PHARMACEUTICALS INC QTRLY LOSS PER SHARE $0.18 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-11T04:14:00.000+03:00",
    "crawled": "2018-05-11T13:08:06.013+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "aurinia",
        "pharmaceutical",
        "inc",
        "aurinia",
        "report",
        "first",
        "quarter",
        "financial",
        "result",
        "operational",
        "highlight",
        "aurinia",
        "pharmaceutical",
        "inc",
        "aurora",
        "phase",
        "iii",
        "trial",
        "lupus",
        "nephritis",
        "remains",
        "track",
        "aurinia",
        "pharmaceutical",
        "inc",
        "continue",
        "aurinia",
        "pharmaceutical",
        "inc",
        "qtrly",
        "loss",
        "per",
        "share",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}